全文获取类型
收费全文 | 1017篇 |
免费 | 250篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 21篇 |
妇产科学 | 28篇 |
基础医学 | 276篇 |
口腔科学 | 3篇 |
临床医学 | 95篇 |
内科学 | 308篇 |
皮肤病学 | 8篇 |
神经病学 | 69篇 |
特种医学 | 17篇 |
外科学 | 114篇 |
综合类 | 33篇 |
预防医学 | 129篇 |
眼科学 | 7篇 |
药学 | 79篇 |
肿瘤学 | 78篇 |
出版年
2021年 | 14篇 |
2020年 | 5篇 |
2019年 | 11篇 |
2018年 | 14篇 |
2017年 | 10篇 |
2016年 | 11篇 |
2015年 | 17篇 |
2014年 | 17篇 |
2013年 | 23篇 |
2012年 | 41篇 |
2011年 | 49篇 |
2010年 | 17篇 |
2009年 | 28篇 |
2008年 | 52篇 |
2007年 | 71篇 |
2006年 | 53篇 |
2005年 | 74篇 |
2004年 | 52篇 |
2003年 | 49篇 |
2002年 | 35篇 |
2001年 | 40篇 |
2000年 | 36篇 |
1999年 | 29篇 |
1998年 | 12篇 |
1997年 | 9篇 |
1996年 | 21篇 |
1995年 | 7篇 |
1994年 | 18篇 |
1993年 | 11篇 |
1992年 | 37篇 |
1991年 | 34篇 |
1990年 | 26篇 |
1989年 | 33篇 |
1988年 | 40篇 |
1987年 | 29篇 |
1986年 | 25篇 |
1985年 | 33篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 10篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1973年 | 6篇 |
1972年 | 14篇 |
1971年 | 8篇 |
排序方式: 共有1269条查询结果,搜索用时 0 毫秒
31.
Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn''s disease. 总被引:4,自引:0,他引:4 下载免费PDF全文
Using two colour immunofluorescence with fluorescein isothiocyanate and phycoerythrin labelled monoclonal antibodies, multi-parameter flow cytometry was used to examine the antigenic characteristics of peripheral blood lymphocytes in whole blood of patients with ulcerative colitis and Crohn's disease who were not taking immunosuppressive drugs. The numbers of CD4+ and CD8+ lymphocytes in patients with ulcerative colitis and Crohn's disease remained unchanged so that the CD4/CD8 ratio was the same as that of normal control subjects. In Crohn's disease there were many activated T cells (CD3+, CD25+). Although natural killer cells in active Crohn's disease were lower than in normal control subjects, cytotoxic T lymphocytes, as defined by CD3+, CD16+, did not differ in patients with inflammatory bowel disease compared with normal control subjects. For B cell subsets, there were differences in Leu-1+ B cells, Leu-8+ B cells, Fc epsilon R+B cells (Leu-16+, Leu-20+), and activated B cells (Leu-12+, Leu-21+) between patients with inflammatory bowel disease and normal control subjects. These differences are compatible with local activation of B cells in the inflamed colon. 相似文献
32.
Frenz MB Dunckley P Camporota L Jewell DP Travis SP 《The American journal of gastroenterology》2005,100(5):1117-1120
The Crohn's disease activity index (CDAI) is the most widely used measure of clinical disease activity in patients entered into clinical trials. The prospective nature of the CDAI calculation precludes its use as a clinical assessment tool. We compared the retrospective evaluation of the CDAI with the prospective evaluation in a heterogeneous patient population of 100 patients with Crohn's disease. The correlation between the two assessment methods was good with an r-value of 0.84 (p < 0,0001). There was a tendency of patients with a high retrospective CDAI to have a lower prospective CDAI which is explained by intention to treat. This study shows that a retrospective assisted evaluation of the CDAI is as accurate as the traditional prospective evaluation. 相似文献
33.
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Czuczman MS Fayad L Delwail V Cartron G Jacobsen E Kuliczkowski K Link BK Pinter-Brown L Radford J Hellmann A Gallop-Evans E DiRienzo CG Goldstein N Gupta I Jewell RC Lin TS Lisby S Schultz M Russell CA Hagenbeek A; Study Investigators 《Blood》2012,119(16):3698-3704
New treatments are required for rituximab-refractory follicular lymphoma (FL). In the present study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg; N = 116). The median age of these patients was 61 years, 47% had high-risk Follicular Lymphoma International Prognostic Index scores, 65% were chemotherapy-refractory, and the median number of prior therapies was 4. The overall response rate was 13% and 10% for the 500-mg and 1000-mg arms, respectively. Among 27 patients refractory to rituximab monotherapy, the overall response rate was 22%. The median progression-free survival was 5.8 months. Forty-six percent of patients demonstrated tumor reduction 3 months after therapy initiation, and the median progression-free survival for these patients was 9.1 months. The most common adverse events included infections, rash, urticaria, fatigue, and pruritus. Three patients experienced grade 3 infusion-related reactions, none of which were considered serious events. Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a subset of patients. Ofatumumab was well tolerated and modestly active in this heavily pretreated, rituximab-refractory population and is therefore now being studied in less refractory FL and in combination with other agents in various B-cell neoplasms. The present study was registered at www.clinicaltrials.gov as NCT00394836. 相似文献
34.
Czuczman MS Hess G Gadeberg OV Pedersen LM Goldstein N Gupta I Jewell RC Lin TS Lisby S Strange C Windfeld K Viardot A; Study Investigators 《British journal of haematology》2012,157(4):438-445
An international, Phase II trial was conducted to assess two doses of ofatumumab, a human CD20 monoclonal antibody, combined with cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), prednisone (100 mg days 3–7) and vincristine (1·4 mg/m2) (O‐CHOP), as frontline treatment for follicular lymphoma (FL). 59 patients with previously untreated FL were randomized to ofatumumab 500 mg (n = 29) or 1000 mg (n = 30) day 1, with CHOP on day 3 every 3 weeks for six cycles. Median duration of FL was 0·1 years for both dose groups; 34% and 38% of patients had high‐risk Follicular Lymphoma International Prognostic Index (FLIPI) scores in the 500‐ and 1000‐mg dose groups, respectively. Overall response rate was 90% for the 500‐mg group and 100% for the 1000‐mg group. 62% of patients achieved complete response (CR)/unconfirmed CR (CRu). 76% of patients with FLIPI score 3–5 attained CR/CRu. Longer follow‐up time is needed for analysis of survival end points. The most common Common Terminology Criteria grade 3–4 investigator‐reported adverse events were leucopenia (29%) and neutropenia (22%). No deaths have been reported. O‐CHOP was safe and efficacious in patients with previously untreated FL, including high‐risk FLIPI groups. This trial was registered at www.clinicaltrials.gov (NCT00494780). 相似文献
35.
36.
37.
38.
Samuel M. Goldman MD MPH Freya Kamel PhD G. Webster Ross MD Sarah A. Jewell MD MPH Connie Marras MD PhD Jane A. Hoppin ScD David M. Umbach PhD Grace S. Bhudhikanok PhD Cheryl Meng MS Monica Korell MPH Kathleen Comyns MPH Robert A. Hauser MD Joseph Jankovic MD Stewart A. Factor DO Susan Bressman MD Kelly E. Lyons PhD Dale P. Sandler PhD J. William Langston MD Caroline M. Tanner MD PhD 《Movement disorders》2014,29(9):1171-1180
Increased gut permeability, inflammation, and colonic α‐synuclein pathology are present in early Parkinson's disease (PD) and have been proposed to contribute to PD pathogenesis. Peptidoglycan is a structural component of the bacterial cell wall. Peptidoglycan recognition proteins (PGRPs) maintain healthy gut microbial flora by regulating the immune response to both commensal and harmful bacteria. We tested the hypothesis that variants in genes that encode PGRPs are associated with PD risk. Participants in two independent case‐control studies were genotyped for 30 single‐nucleotide polymorphisms (SNPs) in the four PGLYRP genes. Using logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for potential confounding variables, we conducted analyses in each study, separately and pooled. One SNP failed the assay, and three had little to no variation. The ORs were similar in both study populations. In pooled analyses, three of seven PGLYRP2 SNPs (rs3813135, rs733731, rs892145), one of five PGLYRP3 SNPs (rs2987763), and six of nine PGLYRP4 SNPs (rs10888557, rs12063091, rs3006440, rs3006448, rs3006458, and rs3014864) were significantly associated with PD risk. Association was strongest for PGLYRP4 5'untranslated region (UTR) SNP rs10888557 (GG reference, CG OR 0.6 [95%CI 0.4‐0.9], CC OR 0.15 [95%CI 0.04‐0.6]; log‐additive P‐trend, 0.0004). Common variants in PGLYRP genes are associated with PD risk in two independent studies. These results require replication, but they are consistent with hypotheses of a causative role for the gut microbiota and gastrointestinal immune response in PD. © 2014 International Parkinson and Movement Disorder Society 相似文献
39.
M Roussomoustakaki J Satsangi K Welsh E Louis G Fanning S Targan C Landers DP Jewell 《Gastroenterology》1997,112(6):1845-1853
BACKGROUND & AIMS: Recent studies have suggested that HLA DRB1*0103 and allele 2 of the interleukin 1 receptor antagonist (IL-1RA) gene predict severe and extensive ulcerative colitis, respectively. The aim of this study was to test these hypotheses in patients undergoing surgery for their colitis. METHODS: HLA DRB1 and DQB1 genotyping was performed in 99 patients and 472 controls. Genotyping for polymorphisms of genes encoding tumor necrosis factor alpha and IL-1RA was performed in 107 patients and 89 controls. Measurement of antineutrophil cytoplasmic antibody (ANCA) was performed in 72 patients and 58 healthy subjects by fixed neutrophil enzyme-linked immunosorbent assay and indirect immunofluorescence. RESULTS: The DRB1*0103 allele was increased in patients (14.1% vs. 3.2% in controls; P < 1 x 10[-5]). This association was greatest in patients with extensive disease (15.8%; P < 0.0001) or extraintestinal manifestations (22.8%; P < 0.0001): mouth ulcers (25.8%; P < 0.0001), arthritis (27.2%; P < 0.0001), and uveitis (35.7%; P < 0.0001). The DRB1*04 alleles were reduced in patients (P = 0.005). Differences were noted between extensive and distal disease in the frequency of allele 2 of IL-1RA (10.9% in distal vs. 28.6% in extensive; P = 0.01) and allele 2 homozygosity. ANCA was detected in 76.4% of patients. Carriage of IL-1RA allele 2 and tumor necrosis factor 2 allele was increased in ANCA-positive patients. CONCLUSIONS: Genetic markers may predict disease behavior in ulcerative colitis. (Gastroenterology 1997 Jun;112(6):1845-53) 相似文献
40.
Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects. 下载免费PDF全文
Studies have been made of mucus glycoprotein biosynthesis in different regions of the lower gastrointestinal tract in normal patients and those with ulcerative colitis (UC), active or inactive, by means of 3H-glucosamine (3H-GlcNH2)--35S-sulphate double labelling of epithelial biopsy specimens under culture conditions. The time based rate of 3H-GlcNH2 labelling of mucus in rectal tissue was similar to that in active or inactive UC whereas the rate of 35SO4(2) labelling was significantly increased in active disease. The 3H specific activities measuring the amount of isotopic incorporation into surface and tissue mucus glycoproteins were increased in patients with active UC compared with normal or inactive subjects. The 35S specific activities did not differ significantly between patients with active UC and those in remission. In the rectum, glycosylation of mucus glycoproteins decreases with the increasing age of the patient. Regional differences in 3H-labelling of mucus components are reported for ascending colon, transverse colon, sigmoid colon, and rectum. Sulphation (35S-labelling) was higher in all parts of the colon in left sided UC. Results point to accelerated glycosylation of core proteins in the active phase of UC. 相似文献